Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03448731
Other study ID # DERMIA
Secondary ID 2017-004413-98
Status Completed
Phase Phase 2
First received
Last updated
Start date May 10, 2018
Est. completion date April 6, 2020

Study information

Verified date April 2020
Source Fundacion CRIS de Investigación para Vencer el Cáncer
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Clinical evidence has suggested that sub-antimicrobial doses of doxycycline may have the potential to treat inflammatory lesions of acne. The efficacy of doses below 100 mg/day of doxycycline in the prevention of skin toxicity in patients with treated with Epidermal Growth Factor Receptor (EGFR)-targeted therapies has never been studied. Therefore, the aim of the present study is to describe the efficacy of doxycycline 50 or 100 mg per day in the prevention of skin toxicity in patients with metastatic Colorectal cancer (mCRC) treated with anti-EGFR in combination with chemotherapy.


Recruitment information / eligibility

Status Completed
Enrollment 34
Est. completion date April 6, 2020
Est. primary completion date April 6, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Man or woman at least 18 years old

- Capable of understanding, signing and dating an informed consent approved by an Independent Ethics Committee (IEC)

- Histologically confirmed adenocarcinoma of the colon or rectum in patients with initially unresectable metastatic (M1) disease

- Wild-type RAS tumour status confirmed before study inclusion at local institution

- Patients who have a treatment plan based on FOLFOX + anti-EGFR or FOLFIRI + anti-EGFR, as first-line treatment of mCRC

- Eastern Cooperative Oncology Group (ECOG) performance status =2

- Adequate bone marrow function: neutrophils =1.5 x109/L; platelets =100 x109/L; haemoglobin =9 g/dL

- Hepatic, renal and metabolic function as follows: Total bilirubin count =1.5 x upper limit of normal (ULN), Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) <5 x ULN; Renal function, calculated as creatinine clearance or 24-hour creatinine clearance =50 mL/min; Magnesium > lower limit of normal (LLN)

Exclusion Criteria:

- History of prior or concurrent central nervous system (CNS) metastases

- History of another primary cancer, except: curatively treated in situ cervical cancer, or curatively resected non-melanoma skin cancer, or other primary solid tumour curatively treated with no known active disease present and no treatment administered for =5 years before treatment initiation

- Known hypersensitivity to tetracyclines

- Prior chemotherapy or other systemic anticancer therapy for treatment of metastatic colorectal carcinoma

- Prior adjuvant chemotherapy for colorectal cancer terminated less than 6 months before metastatic disease was diagnosed

- Unresolved toxicities of a previous systemic treatment that, in the opinion of the investigator, cause the patient unfit for inclusion

- Prior anti-epidermal growth factor receptor (EGFR) antibody therapy (e.g., cetuximab), antivascular endothelial growth factor (VEGF) or treatment with small molecule EGFR inhibitors (e.g., erlotinib)

- Prior hormonal therapy, immunotherapy or approved or experimental antibody/proteins =30 days before inclusion.

- Significant cardiovascular disease including unstable angina or myocardial infarction within 12 months before initiating study treatment or a history of ventricular arrhythmia

- History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis on baseline chest computed tomography (CT)

- Treatment for systemic infection within 14 days before the start of study treatment

- Acute or subacute intestinal occlusion and/or active inflammatory bowel disease or other bowel disease that causes chronic diarrhoea (defined as grade = 2 diarrhoea according to Common Terminology Criteria for Adverse Events (CTCAE)

- Clinically significant peripheral sensory neuropathy

- Evidence of previous acute hypersensitivity reaction, of any grade, to any component of the treatment

- History of Gilbert disease or known dihydropyrimidine deficiency syndrome

- Recent gastroduodenal ulcer to be active or uncontrolled

- Recent pulmonary embolism, deep vein thrombosis, or other significant venous event

- Pre-existing bleeding diathesis and/or coagulopathy with exception of well-controlled anticoagulation therapy

- Recent major surgical procedure, open biopsy, or significant traumatic injury not yet recovered from prior major surgery

- History of any disease that may increase the risks associated with study participation or may interfere with the interpretation of study results.

- Known positive test for human immunodeficiency virus infection, hepatitis C virus, chronic active hepatitis B infection

- Any disorder that compromises the patient's ability to provide written informed consent and/or comply with study procedures

- Any investigational agent within 30 days prior to inclusion

- Pregnant or breastfeeding woman

- Surgery (excluding diagnostic biopsy or placement of a central venous catheter) and/or radiotherapy within 28 days prior to inclusion in the study.

- Male or female of childbearing age who do not agree with taking adequate contraceptive precautions, i.e. use contraception double barrier (e.g. diaphragm plus condoms) or abstinence during the course of the study and for 6 months after the last administration of study drug for women and 1 month for men

- The patient is unwilling or unable to meet the requirements of the study. Psychological, geographical, familial or sociological conditions that potentially prevent compliance with the study protocol and follow-up schedule. These conditions should be discussed with the patient before inclusion in the trial.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Doxycycline 50Mg Tablet
Doxycycline administered p.o once daily at a 50 mg dose for 6 weeks beginning on Day -1

Locations

Country Name City State
Spain Hospital Punta Europa Algeciras
Spain Hospital San Pedro de Alcántara Cáceres
Spain Hospital Puerta del Mar Cadiz
Spain Hospital Puerto Real Cadiz
Spain Hospital Clinico San Cecilio Granada
Spain Hospital Juan Ramón Jiménez Huelva
Spain Hospital de Jerez Jerez De La Frontera
Spain Hospital Virgen Macarena Sevilla

Sponsors (3)

Lead Sponsor Collaborator
Fundacion CRIS de Investigación para Vencer el Cáncer Amgen, Apices Soluciones S.L.

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Efficacy in the prevention of skin toxicity Monitoring of skin toxicities graded according to National Cancer Institute Common Terminology Criteria for Adverse Events During 6-week skin treatment
Secondary Quality of life of patients during the treatment Change in Dermatology Life Quality Index (DLQI) score Up to 7 weeks
Secondary Incidence of Treatment-Emergent Adverse Events Number of adverse events per patient Up to 6 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04929834 - Novel Skin Care for Immunotherapy- Related Dermatologic Toxicities N/A
Completed NCT04929847 - Novel Skin Care for Chemotherapy- Related Dermatologic Toxicities N/A
Not yet recruiting NCT03606954 - Potency of Topical Corticosteroids in Combination Preparations Phase 4
Completed NCT01976481 - Serum 25-OH Vitamin D Modulation by Sunbed Use According to EU Guideline EN 60335-2-27 N/A
Recruiting NCT05109858 - Skin Toxicity by Oncological Therapies
Completed NCT00871429 - Skin Care for Cancer Patients: A Product Satisfaction Survey N/A
Recruiting NCT04469075 - Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields Phase 2
Recruiting NCT04650256 - Application of Chinese Herbal Complementary and Alternative Medicine (CAM) to Improve Human Health and to Further Botanical and Horticultural Sciences N/A
Terminated NCT01317433 - Pre-emptive Cycline Treatment on Cetuximab Induced Skin Toxicity in Colorectal Cancer N/A
Active, not recruiting NCT03167268 - Panitumumab Skin Toxicity Prevention Trial Phase 2
Recruiting NCT06118047 - Crisaborole Ointment for Skin Toxicity Induced by Cetuximab Phase 2